Chordomas are rare neoplasms arising along the axial skeleton. Up to now, the most suitable therapeutic approach is based on a combination of surgical excision and radiotherapy. Chemotherapy in not applied due to its reported low efficacy. Recently, evidence on the efficacy of Imatinib mesylate in two patients has been reported. We analyzed 14 chordoma samples for the expression of the Imatinib mesylate targets by means of RT-PCR and immunohistochemistry and found that PDGFRα and PDGFRβ are in some cases expressed in neoplastic cells, while the stromal counterpart of the same tumor shows the above receptors. Findings on the PDGFA/PDGFB expression suggest a receptor-activated status. Our study provides new insights into the specific localization of Imatinib mesylate targets in skull base chordomas that could be taken into account for the setting up of a pharmacological treatment for this tumor.

Expression study of receptor tyrosine kinase targets of Imatinib mesylate in skull base chordomas / F. Orzan, M.R. Terreni, M. Longoni, N. Boari, P. Mortini, C. Doglioni, P. Riva. - In: ONCOLOGY REPORTS. - ISSN 1021-335X. - 18:1(2007), pp. 249-252.

Expression study of receptor tyrosine kinase targets of Imatinib mesylate in skull base chordomas

P. Riva
Ultimo
2007

Abstract

Chordomas are rare neoplasms arising along the axial skeleton. Up to now, the most suitable therapeutic approach is based on a combination of surgical excision and radiotherapy. Chemotherapy in not applied due to its reported low efficacy. Recently, evidence on the efficacy of Imatinib mesylate in two patients has been reported. We analyzed 14 chordoma samples for the expression of the Imatinib mesylate targets by means of RT-PCR and immunohistochemistry and found that PDGFRα and PDGFRβ are in some cases expressed in neoplastic cells, while the stromal counterpart of the same tumor shows the above receptors. Findings on the PDGFA/PDGFB expression suggest a receptor-activated status. Our study provides new insights into the specific localization of Imatinib mesylate targets in skull base chordomas that could be taken into account for the setting up of a pharmacological treatment for this tumor.
Imatinib mesylate; KIT; PDGFR; Skull base chordoma
Settore BIO/13 - Biologia Applicata
http://www.spandidos-publications.com/or/article.jsp?article_id=or_18_1_249
Article (author)
File in questo prodotto:
File Dimensione Formato  
Orzan et al 2007-Manuscript.pdf

accesso aperto

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 586.57 kB
Formato Adobe PDF
586.57 kB Adobe PDF Visualizza/Apri
or_18_1_249_PDF.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 208.32 kB
Formato Adobe PDF
208.32 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/34944
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 18
social impact